Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America

Rémi Forrat, Gustavo H. Dayan, Carlos A. DiazGranados, Matthew Bonaparte, Thelma Laot, Maria Rosario Capeding, Leilani Sanchez, Diana Leticia Coronel, Humberto Reynales, Danaya Chansinghakul, Sri Rezeki S. Hadinegoro, Ana Paula Perroud, Carina Frago, Betzana Zambrano, Tifany Machabert, Yukun Wu, Alexander Luedtke, Brenda Price, Claire Vigne, Owen HaneyStephen J. Savarino, Alain Bouckenooghe, Fernando Noriega

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (
Original languageEnglish
Pages (from-to)1003-1012
Number of pages10
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume73
Issue number6
DOIs
Publication statusPublished - 15 Sep 2021

Keywords

  • CYD-TDV
  • dengue
  • serostatus
  • VCD

Fingerprint

Dive into the research topics of 'Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America'. Together they form a unique fingerprint.

Cite this